Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 26, 2026

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry
11:02

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry

Published on: January 20, 2017

9.6K

[Sarcoidosis].

Florence Jeny1, Dominique Valeyre1

  • 1AP-HP, service de pneumologie, hôpital Avicenne, Bobigny, France EA2363, « Hypoxie et Poumon », Paris-13 SMBH, Bobigny, France.

La Revue Du Praticien
|April 16, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities.

ERJ open research·2026
Same author

Pulmonary sarcoïdosis presenting as acute hypoxemic respiratory failure.

Respiratory medicine and research·2026
Same author

Considering molecular pharmacology for sarcoidosis treatment.

The Lancet. Respiratory medicine·2026
Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Sarcoidosis is a rare systemic disease affecting lungs and lymphatics. Management requires tracking organ dysfunction and patient discomfort, with corticosteroids as a primary treatment option.

Area of Science:

  • Systemic Inflammatory Diseases
  • Granulomatous Disorders

Background:

  • Sarcoidosis is a rare systemic granulomatosis of unknown etiology.
  • It commonly affects the lungs and lymphatic system.
  • Clinical presentations and disease progression are highly variable, complicating diagnosis and management.

Purpose of the Study:

  • To highlight the diagnostic and therapeutic challenges in managing sarcoidosis.
  • To emphasize the importance of monitoring organ dysfunction and patient quality of life.
  • To outline current treatment strategies for sarcoidosis.

Main Methods:

  • This abstract summarizes current understanding and clinical approaches to sarcoidosis.
  • It reviews diagnostic considerations and monitoring of organ involvement.
Keywords:
Sarcoidosis

Related Experiment Videos

Last Updated: Jan 26, 2026

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry
11:02

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry

Published on: January 20, 2017

9.6K
  • It discusses established and emerging treatment modalities.

    • Main Results:

    • Sarcoidosis frequently involves pulmonary and lymphatic systems.
    • Monitoring for life-threatening (pulmonary, cardiac) and functionally significant (neurological, ophthalmic, renal) organ dysfunctions is crucial.
    • Persistent discomfort significantly impacts patient quality of life.

    Conclusions:

    • Effective sarcoidosis management necessitates vigilant tracking of organ involvement and patient-reported outcomes.
    • Corticosteroids are first-line treatment, despite potential side effects.
    • Immunosuppressants and TNF antagonists serve as second- and third-line options, respectively.